University of Miami’s Miami project successfully completes SCI clinical trial – Medical Xpress

March 8, 2017 University of Miami's Miami Project to Cure Paralysis surgical team preparing for a Schwann cell transplantation. Credit: University of Miami Miller School of Medicine / Miami Project to Cure Paralysis

The Miami Project to Cure Paralysis, at the University of Miami Miller School of Medicine, today announced the publication of its first Food and Drug Administration (FDA) approved Phase I clinical trial involving human nerve cells used to repair the damaged spinal cord, in the February issue of the Journal of Neurotrauma. The cells, known as Schwann cells, are essential for the repair of nerve damage, and long thought to be able to increase recovery after spinal cord injury. The trial, performed at University of Miami / Jackson Memorial Hospital in Miami, is the first in a series designed to evaluate the safety and feasibility of transplanting autologous human Schwann cells to treat individuals with spinal cord injuries.

The trial enrolled subjects with the least chance of natural recovery in order to firstly establish the safety of the cell transplant procedure; specifically, it targeted people with new SCI, less than 30 days after injury, having sustained a trauma-induced lesion between thoracic levels T3-T11 and who were neurologically complete. This was a dose escalation treatment trial testing 3 different doses: 5 million, 10 million, and 15 million Schwann cells. There were a total of 39 people screened for eligibility, 9 were enrolled, and 6 participants were transplanted. The first two participants received the 5 million cell dose, the second two received the 10 million cell dose, and the final two received the 15 million cell dose. Because the Schwann cells, which reside in peripheral nerves, are obtained from a nerve biopsy from each participant, there is reduced concern of immune rejection and immunosuppressant medication is not required. Demonstrating the feasibility of a program involving an autologous cell therapy is critical, given the reduced risk associated with autologous versus allogeneic "off-the-shelf" cell products. Once the cells are removed from the participant, they have to be handled in accordance with current Good Manufacturing Practices (GMP). Because the cells are eventually injected into the spinal cord, this process is required to ensure that the cells are prepared consistently and without contaminants. Each participant was followed intensively for one year after receiving the transplantation surgery, and their neurologic status, medical status, pain symptoms, and muscle spasticity were evaluated. All participants will continue to be monitored for a total of five years after the transplantation.

Subjects enrolled came from both South Florida, the Caribbean, and Latin America reflecting the importance of Miami as a hub for medical advances in these regions. The enrolled subjects did not experience any severe complications as a result of the therapy or the surgery and one subject recovered sufficient neurological function to be classified as incomplete, whereas upon trial entry, he had complete injury. The clinical trial used advanced cell culture methods, expert surgery, and a strong complement of evaluation techniques to study the impact of the cell transplantation. Importantly, the trial successfully determined safety and feasibility for performing a peripheral nerve harvest within 5-30 days of injury followed by an intra-spinal transplantation of autologous cells within 4-7 weeks of injury, even in individuals having sustained severe spinal injury.

This first trial, using cells grown from the subject's own nerves is an important validation of decades of prior work and animal studies. Scientific reviewers commented that "This is a very carefully executed study and the authors are leading the field as the first non-commercial, i.e. purely academic group, in North America to develop a cell preparation for SCI transplantation and to execute on a cell transplantation trial in humans". It is a key milestone for The Miami Project's integrated program that studies spinal cord injury from multiple perspectives. Having now established the safety of Schwann cell transplantation in this initial group of subjects, it will be possible to combine other exciting therapies to amplify neurological recovery.

The video will load shortly

Explore further: Regenerating nerve tissue in spinal cord injuries

More information: Kimberly D Anderson et al, Safety of Autologous Human Schwann Cell Transplantation in Subacute Thoracic Spinal Cord Injury, Journal of Neurotrauma (2017). DOI: 10.1089/neu.2016.4895

Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying ...

Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC) recently enrolled their first subject in a national clinical research trial ...

Physicians at Rush University Medical Center became the first in Illinois to inject AST-OPC1 (oligodendrocyte progenitor cells), an experimental treatment, into the damaged cervical spine of a recently paralyzed man as part ...

Research published today, 30th January 2017 online in the Journal of Cell Biology, has for the first time identified how a bodily protein allows nerves of the peripheral nervous system (PNS) to repair following injury.

A study carried out at the University of Miami Miller School of Medicine for "The Miami Project to Cure Paralysis" has found that transplanting self-donated Schwann cells (SCs, the principal ensheathing cells of the nervous ...

Fragile X syndrome is the most common cause of autism. Even though the single gene that's responsible for it was discovered in 1991, and the disease is detected by a simple blood test, there's no treatment or cure.

A foray into plant biology led one researcher to discover that a natural molecule can repair axons, the thread-like projections that carry electrical signals between cells. Axonal damage is the major culprit underlying disability ...

It takes a villageof neuronsthat is, to process sensory inputs in the brain. For example, when a line appears in our visual field, networks of neurons fire together and send messages throughout the brain to identify ...

Precise knowledge of the connections in the brain the links between all the nerve cells is a prerequisite for better understanding this most complex of organs. Researchers from Heidelberg University have now developed ...

The human brain has the ability to recognise and process a very wide range of sensory stimuli, from which it builds a mental representation. But do these representations change over time? Can we learn to classify and interpret ...

Like the junctions in an electronic circuit between two semiconductors in an integrated computer chip, synapses in the brain constitute the logic of information flow. Simply put, neurons form functional synapses every time ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:
University of Miami's Miami project successfully completes SCI clinical trial - Medical Xpress